^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDH2 overexpression + KRAS wild-type

    i
    Other names: CDH2, Cadherin 2, CDHN, Cadherin 2, Type 1, N-Cadherin (Neuronal), Neural Cadherin, N-Cadherin, Cadherin-2, CDw325, CD325, NCAD, Calcium-Dependent Adhesion Protein, Neuronal, CD325 Antigen, N-Cadherin 1, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 1000
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    N-Cadherin acts as a predictive biomarker for anti-FGFR therapy in KRAS wild-type NSCLC (AACR 2023)
    Therefore, it is essential the identification of new biomarkers that could help to predict more accurately those patients that could benefit from anti-FGFR therapy.Materials and We have treated 15 NSCLC PDX models with high FGFR1 expression levels and variable N-Cadherin expression levels, with the FGFR inhibitor (FGFRi) AZD4547... In conclusion, previous research had underlined N-Cadherin as a potential biomarker of response to FGFRi, while not successful in all contexts. Transcriptome study of PDXs classified as responder or non-responder to FGFRi revealed a differential gene expression pattern, with an upregulation of N-Cadherin pathway observed in the Responder group, while an enrichment of KRAS signaling and KRAS mutations in non-Responders. Furthermore, we validated our finding using a cell line repository that confirm that N-Cadherin could predict FGFR-targeted therapy efficacy but only in the KRAS wildtype context .
    KRAS (KRAS proto-oncogene GTPase) • FGFR (Fibroblast Growth Factor Receptor) • CDH2 (Cadherin 2)
    |
    KRAS mutation • FGFR1 amplification • KRAS wild-type • RAS wild-type • FGFR1 expression • CDH1 expression • CDH2 overexpression + KRAS wild-type • KRAS expression
    |
    fexagratinib (ABSK091)